Pharmacology Drug Class Flashcards: Mechanisms, Uses & Safety Patterns

Study 126 cards on 30 common drug classes: mechanisms, qualified generic-name patterns, common uses, and major safety concepts for nursing and introductory health science.

Про цю колоду

Build a durable pharmacology map with 126 independently authored cards. Six prerequisites define drug classes, mechanisms, agonism, antagonism, inhibition, and how to treat generic-name stems as fallible clues. The remaining 120 cards cover 30 common classes through four separate retrieval directions: class → core mechanism; qualified pattern or representative generics → class; class → common use; and class → major safety concept.

The deck deliberately excludes dosing, prescribing, patient-specific guidance, administration or hold parameters, exhaustive contraindications and interactions, monitoring protocols, brand names, official questions, and clinical cases. Generic-name patterns are clues, never universal rules. Use this deck for study—not clinical decision-making.

Ordering supports learning: prerequisites come first, then five spiral blocks mix six broad topic groups. Same-class variants stay at least three unrelated cards apart, alternating mechanism, recognition, common-use, and safety recall instead of forming predictable runs.

Open Study Contributor independently authored this standalone deck from common pharmacology knowledge checked against WHO, FDA, and NIH/NCBI sources. Organization names identify sources only; no affiliation or endorsement is claimed.

Картки в цій колоді

  1. Картка 1

    Питання

    What is a drug class?

    Відповідь

    A group of drugs linked by a shared mechanism, target, structure, therapeutic use, or a combination of these features.

  2. Картка 2

    Питання

    What does mechanism of action mean?

    Відповідь

    How a drug produces its effects at a molecular, cellular, or physiological target.

  3. Картка 3

    Питання

    What is a receptor agonist?

    Відповідь

    A drug that binds to a receptor and activates it to produce a response.

  4. Картка 4

    Питання

    What is a receptor antagonist?

    Відповідь

    A drug that binds to a receptor and blocks or reduces activation by an agonist.

  5. Картка 5

    Питання

    What does it mean when a drug inhibits an enzyme or transporter?

    Відповідь

    It reduces that protein's activity, changing the movement or conversion of its usual substrates.

  6. Картка 6

    Питання

    How should generic-name stems be used to recognize drug classes?

    Відповідь

    As clues, not universal rules. Confirm the actual drug because exceptions and overlapping stems exist.

  7. Картка 7

    Питання

    ACE inhibitors: core mechanism?

    Відповідь

    They inhibit angiotensin-converting enzyme, reducing angiotensin II and aldosterone while increasing bradykinin.

  8. Картка 8

    Питання

    SSRIs: core mechanism?

    Відповідь

    They inhibit the serotonin transporter, increasing serotonin signaling in the synaptic cleft.

  9. Картка 9

    Питання

    Biguanides: core mechanism?

    Відповідь

    Metformin mainly reduces hepatic glucose production and improves insulin sensitivity without directly stimulating insulin release.

  10. Картка 10

    Питання

    Penicillins: core mechanism?

    Відповідь

    Their beta-lactam ring binds penicillin-binding proteins and disrupts bacterial cell-wall synthesis.

  11. Картка 11

    Питання

    Which class is often suggested by the ending -pril?

    Відповідь

    ACE inhibitors. Examples include lisinopril and enalapril, but a name stem is only a clue.

  12. Картка 12

    Питання

    Proton-pump inhibitors: core mechanism?

    Відповідь

    They inhibit the H+/K+ ATPase proton pump in gastric parietal cells, strongly reducing acid secretion.

  13. Картка 13

    Питання

    SSRIs: common uses?

    Відповідь

    Depression and several anxiety-related disorders; the approved indications differ by agent.

  14. Картка 14

    Питання

    NSAIDs: core mechanism?

    Відповідь

    They inhibit cyclooxygenase enzymes, reducing prostaglandin synthesis.

  15. Картка 15

    Питання

    Biguanides: major safety concepts?

    Відповідь

    Gastrointestinal effects are common; vitamin B12 can fall with long use, and lactic acidosis is rare but serious.

  16. Картка 16

    Питання

    Which class is often suggested by the ending -cillin?

    Відповідь

    Penicillins, such as amoxicillin and piperacillin. The stem does not describe spectrum or resistance.

  17. Картка 17

    Питання

    ACE inhibitors: common uses?

    Відповідь

    Hypertension and selected heart-failure, post-myocardial-infarction, and kidney-protection indications.

  18. Картка 18

    Питання

    Proton-pump inhibitors: major safety concepts?

    Відповідь

    Possible concerns include hypomagnesemia and enteric infection risk. Many other long-term links are observational rather than proven causal effects.

  19. Картка 19

    Питання

    Which class is often suggested by -oxetine or -opram?

    Відповідь

    SSRIs, but not universally. Sertraline and fluvoxamine are exceptions, and some stems overlap other classes.

  20. Картка 20

    Питання

    NSAIDs: common uses?

    Відповідь

    Pain, inflammation, and fever; individual agents also have more specific uses.

  21. Картка 21

    Питання

    Metformin belongs to which drug class?

    Відповідь

    Biguanides. Metformin is the main widely used member, so there is no useful class-wide suffix rule.

  22. Картка 22

    Питання

    Penicillins: major safety concepts?

    Відповідь

    Hypersensitivity can range from rash to anaphylaxis; diarrhea and antibiotic-associated colitis are additional concerns.

  23. Картка 23

    Питання

    ACE inhibitors: major safety concepts?

    Відповідь

    Cough, hyperkalemia, kidney-function changes, angioedema, and fetal harm are major class concerns.

  24. Картка 24

    Питання

    Proton-pump inhibitors: common uses?

    Відповідь

    Acid-related disorders such as GERD, erosive esophagitis, and peptic-ulcer disease.

  25. Картка 25

    Питання

    SSRIs: major safety concepts?

    Відповідь

    Serotonin syndrome, bleeding and hyponatremia risks, sexual dysfunction, and the antidepressant suicidality warning for younger people.

  26. Картка 26

    Питання

    Ibuprofen, naproxen, and ketorolac belong to which class?

    Відповідь

    NSAIDs. The class has no single reliable generic-name suffix.

  27. Картка 27

    Питання

    Biguanides: common use?

    Відповідь

    Type 2 diabetes.

  28. Картка 28

    Питання

    Penicillins: common use?

    Відповідь

    Treatment of susceptible bacterial infections; the spectrum differs substantially among individual penicillins.

  29. Картка 29

    Питання

    Which class is often suggested by the ending -prazole?

    Відповідь

    Proton-pump inhibitors, such as omeprazole and pantoprazole. Confirm the individual drug.

  30. Картка 30

    Питання

    NSAIDs: major safety concepts?

    Відповідь

    Gastrointestinal bleeding, kidney injury, fluid retention, and cardiovascular events are key risks; FDA also warns about use from about 20 weeks of pregnancy.

  31. Картка 31

    Питання

    Sulfonylureas: core mechanism?

    Відповідь

    They close ATP-sensitive potassium channels in pancreatic beta cells, triggering insulin release even when glucose is not high.

  32. Картка 32

    Питання

    H2 blockers: core mechanism?

    Відповідь

    They competitively block histamine H2 receptors on gastric parietal cells, reducing acid secretion.

  33. Картка 33

    Питання

    SNRIs: core mechanism?

    Відповідь

    They inhibit serotonin and norepinephrine reuptake transporters, increasing both transmitters in synapses.

  34. Картка 34

    Питання

    Opioid analgesics: core mechanism?

    Відповідь

    They activate opioid receptors; many important analgesic effects and toxicities are mediated through mu receptors.

  35. Картка 35

    Питання

    Glipizide, glyburide, and glimepiride belong to which class?

    Відповідь

    Sulfonylureas. Their names offer clues, but the broad ending -ide is not class-specific.

  36. Картка 36

    Питання

    ARBs: core mechanism?

    Відповідь

    They block angiotensin II at AT1 receptors, reducing vasoconstriction and aldosterone effects.

  37. Картка 37

    Питання

    H2 blockers: common uses?

    Відповідь

    Acid-related disorders such as heartburn, GERD, and gastric or duodenal ulcers.

  38. Картка 38

    Питання

    Cephalosporins: core mechanism?

    Відповідь

    Their beta-lactam ring binds penicillin-binding proteins and disrupts bacterial cell-wall synthesis.

  39. Картка 39

    Питання

    SNRIs: major safety concepts?

    Відповідь

    Serotonin syndrome, blood-pressure increases, discontinuation symptoms, and the antidepressant suicidality warning for younger people.

  40. Картка 40

    Питання

    Morphine, oxycodone, and fentanyl belong to which broad class?

    Відповідь

    Opioid analgesics. The class has no single reliable generic-name suffix.

  41. Картка 41

    Питання

    Sulfonylureas: common use?

    Відповідь

    Type 2 diabetes when increasing pancreatic insulin release is appropriate.

  42. Картка 42

    Питання

    ARBs: major safety concepts?

    Відповідь

    Hyperkalemia, hypotension, kidney-function changes, and fetal harm are major concerns; cough is less common than with ACE inhibitors.

  43. Картка 43

    Питання

    Which class is often suggested by the ending -tidine?

    Відповідь

    H2 receptor blockers, such as famotidine and cimetidine. Confirm the individual drug.

  44. Картка 44

    Питання

    Cephalosporins: common use?

    Відповідь

    Treatment of susceptible bacterial infections; antibacterial spectrum varies widely by agent and generation.

  45. Картка 45

    Питання

    Which name endings can suggest an SNRI?

    Відповідь

    -faxine or sometimes -oxetine, but neither is decisive. The -oxetine ending also appears in some SSRIs.

  46. Картка 46

    Питання

    Opioid analgesics: major safety concepts?

    Відповідь

    Respiratory depression, sedation, constipation, tolerance, dependence, and overdose; benzodiazepines and other depressants increase danger.

  47. Картка 47

    Питання

    Sulfonylureas: major safety concepts?

    Відповідь

    Hypoglycemia and weight gain are the main class patterns, with risk differing among agents and clinical contexts.

  48. Картка 48

    Питання

    ARBs: common uses?

    Відповідь

    Hypertension and selected heart-failure and kidney-protection indications.

  49. Картка 49

    Питання

    H2 blockers: major safety concepts?

    Відповідь

    They are usually well tolerated, but confusion or other CNS effects can occur with reduced clearance; cimetidine has many interactions.

  50. Картка 50

    Питання

    Which class is often suggested by cef- or ceph-?

    Відповідь

    Cephalosporins, such as cefazolin and cephalexin. The name does not reveal the full spectrum.

  51. Картка 51

    Питання

    SNRIs: common uses?

    Відповідь

    Depression and anxiety disorders; selected agents also treat neuropathic pain or fibromyalgia.

  52. Картка 52

    Питання

    Opioid analgesics: common uses?

    Відповідь

    Analgesia for selected severe pain and perioperative settings; individual opioids also have other specific uses.

  53. Картка 53

    Питання

    Which class is often suggested by the ending -sartan?

    Відповідь

    Angiotensin II receptor blockers, or ARBs. Examples include losartan and valsartan.

  54. Картка 54

    Питання

    Cephalosporins: major safety concepts?

    Відповідь

    Hypersensitivity and antibiotic-associated diarrhea are important; penicillin cross-reactivity depends largely on similar side chains.

  55. Картка 55

    Питання

    Beta2 agonists: core mechanism?

    Відповідь

    They activate beta2 receptors, increasing cAMP and relaxing airway smooth muscle.

  56. Картка 56

    Питання

    Beta blockers: core mechanism?

    Відповідь

    They antagonize beta-adrenergic receptors; beta1 blockade can reduce heart rate, contractility, and renin release.

  57. Картка 57

    Питання

    Systemic corticosteroids: core mechanism?

    Відповідь

    They bind intracellular glucocorticoid receptors and alter gene transcription, reducing inflammatory and immune signaling.

  58. Картка 58

    Питання

    Benzodiazepines: core mechanism?

    Відповідь

    They positively modulate GABA-A receptors, increasing the frequency of chloride-channel opening when GABA is present.

  59. Картка 59

    Питання

    Which class is often suggested by the ending -terol?

    Відповідь

    Beta2 agonist bronchodilators, such as formoterol and salmeterol. Albuterol is a familiar exception.

  60. Картка 60

    Питання

    Macrolides: core mechanism?

    Відповідь

    They bind the bacterial 50S ribosomal subunit and inhibit protein synthesis.

  61. Картка 61

    Питання

    Beta blockers: common uses?

    Відповідь

    Selected cardiovascular conditions such as arrhythmias, ischemic heart disease, heart failure, and hypertension; some agents have noncardiac uses.

  62. Картка 62

    Питання

    GLP-1 receptor agonists: core mechanism?

    Відповідь

    They activate GLP-1 receptors, increasing glucose-dependent insulin release, suppressing glucagon, and slowing gastric emptying.

  63. Картка 63

    Питання

    Systemic corticosteroids: major safety concepts?

    Відповідь

    Infection, hyperglycemia, osteoporosis, and hypothalamic-pituitary-adrenal suppression; risks rise with systemic exposure and duration.

    Abstract pharmacology study cover showing an unmarked capsule and tablet encircled by six colorful receptor, channel, enzyme, and signaling motifs on a navy field.

    126 карток

    Pharmacology Drug Class Flashcards: Mechanisms, Uses & Safety Patterns

    Вивчати цю колоду безкоштовно

    Відкриється Nibomo, і ви зможете почати навчання.

  64. Картка 64

    Питання

    Which endings often suggest a benzodiazepine?

    Відповідь

    -azepam or -azolam, as in diazepam or midazolam. Not every sedative with a similar ending belongs to this class.

  65. Картка 65

    Питання

    Beta2 agonists: common use?

    Відповідь

    Bronchodilation in asthma or COPD regimens; short- and long-acting agents play different roles.

  66. Картка 66

    Питання

    Macrolides: major safety concepts?

    Відповідь

    Gastrointestinal effects, QT prolongation, and clinically important interactions that vary by agent.

  67. Картка 67

    Питання

    Which class is often suggested by the ending -olol?

    Відповідь

    Beta blockers, such as metoprolol and propranolol. Receptor selectivity still varies by agent.

  68. Картка 68

    Питання

    GLP-1 receptor agonists: common uses?

    Відповідь

    Type 2 diabetes; selected agents are also approved for chronic weight management and cardiovascular-risk reduction.

  69. Картка 69

    Питання

    Which patterns often suggest a systemic corticosteroid?

    Відповідь

    -sone or -olone, as in prednisone or prednisolone, but these endings are not unique to the class.

  70. Картка 70

    Питання

    Benzodiazepines: major safety concepts?

    Відповідь

    Sedation, dependence and withdrawal, plus respiratory depression—especially with opioids, alcohol, or other CNS depressants.

  71. Картка 71

    Питання

    Beta2 agonists: major safety concepts?

    Відповідь

    Tremor, palpitations or tachycardia, hypokalemia, and rare paradoxical bronchospasm.

  72. Картка 72

    Питання

    Macrolides: common use?

    Відповідь

    Treatment of selected susceptible bacterial infections, including some respiratory and atypical pathogens.

  73. Картка 73

    Питання

    Beta blockers: major safety concepts?

    Відповідь

    Bradycardia and hypotension; nonselective agents can cause bronchospasm, and the class can mask adrenergic signs of hypoglycemia.

  74. Картка 74

    Питання

    Which class is often suggested by -glutide?

    Відповідь

    GLP-1 receptor agonists, such as semaglutide and liraglutide. Exenatide and lixisenatide show the pattern is not universal.

  75. Картка 75

    Питання

    Systemic corticosteroids: common uses?

    Відповідь

    Inflammatory, allergic, and autoimmune disorders, with the route and agent chosen for the condition.

  76. Картка 76

    Питання

    Benzodiazepines: common uses?

    Відповідь

    Anxiety, seizures, procedural sedation, or alcohol withdrawal, depending on the agent and setting.

  77. Картка 77

    Питання

    Which class is often suggested by the ending -thromycin?

    Відповідь

    Macrolide antibiotics, such as azithromycin and clarithromycin. Confirm the individual agent.

  78. Картка 78

    Питання

    GLP-1 receptor agonists: major safety concepts?

    Відповідь

    Gastrointestinal effects are common; gallbladder disease and pancreatitis are warnings, and some labels warn about thyroid C-cell tumors.

  79. Картка 79

    Питання

    Second-generation antipsychotics: core mechanism?

    Відповідь

    Most modulate dopamine D2 and serotonin 5-HT2A signaling, but receptor profiles vary substantially by agent.

  80. Картка 80

    Питання

    Tetracyclines: core mechanism?

    Відповідь

    They bind the bacterial 30S ribosomal subunit and inhibit protein synthesis.

  81. Картка 81

    Питання

    Dihydropyridine calcium-channel blockers: core mechanism?

    Відповідь

    They block L-type calcium channels mainly in vascular smooth muscle, causing arteriolar relaxation.

  82. Картка 82

    Питання

    Inhaled antimuscarinics: core mechanism?

    Відповідь

    They block airway muscarinic receptors, reducing vagal bronchoconstriction and promoting bronchodilation.

  83. Картка 83

    Питання

    Which endings often suggest a second-generation antipsychotic?

    Відповідь

    -apine or -idone often appear, but many members use other endings and the stems are not class-specific.

  84. Картка 84

    Питання

    SGLT2 inhibitors: core mechanism?

    Відповідь

    They inhibit renal sodium-glucose cotransporter 2, increasing urinary glucose and sodium excretion.

  85. Картка 85

    Питання

    Tetracyclines: common uses?

    Відповідь

    Selected susceptible bacterial infections and, for some agents, acne or rosacea.

  86. Картка 86

    Питання

    Bisphosphonates: core mechanism?

    Відповідь

    They bind bone mineral and inhibit osteoclast-mediated bone resorption.

  87. Картка 87

    Питання

    Dihydropyridine calcium-channel blockers: major safety concepts?

    Відповідь

    Peripheral edema, flushing, headache, dizziness, and hypotension are characteristic patterns.

  88. Картка 88

    Питання

    Which class is often suggested by the ending -tropium?

    Відповідь

    Inhaled antimuscarinic bronchodilators, such as ipratropium and tiotropium. Several class members use other endings.

  89. Картка 89

    Питання

    Second-generation antipsychotics: common uses?

    Відповідь

    Schizophrenia and selected bipolar or other psychiatric indications; approvals differ by agent.

  90. Картка 90

    Питання

    SGLT2 inhibitors: major safety concepts?

    Відповідь

    Genital infections, volume depletion, ketoacidosis, and rare necrotizing infection of the perineum.

  91. Картка 91

    Питання

    Which class is often suggested by the ending -cycline?

    Відповідь

    Tetracycline antibiotics, such as doxycycline and minocycline. Confirm the individual drug.

  92. Картка 92

    Питання

    Bisphosphonates: common uses?

    Відповідь

    Osteoporosis and selected disorders with excessive bone resorption, including Paget disease or malignancy-related bone disease.

  93. Картка 93

    Питання

    Which class is often suggested by the ending -dipine?

    Відповідь

    Dihydropyridine calcium-channel blockers, such as amlodipine and nifedipine.

  94. Картка 94

    Питання

    Inhaled antimuscarinics: major safety concepts?

    Відповідь

    Dry mouth, urinary retention, tachycardia, and eye exposure that may worsen narrow-angle glaucoma.

  95. Картка 95

    Питання

    Second-generation antipsychotics: major safety concepts?

    Відповідь

    Metabolic effects, movement disorders, QT effects, and neuroleptic malignant syndrome; labels warn about increased mortality in elderly patients with dementia-related psychosis.

  96. Картка 96

    Питання

    SGLT2 inhibitors: common uses?

    Відповідь

    Type 2 diabetes; selected agents also treat heart failure or chronic kidney disease.

  97. Картка 97

    Питання

    Tetracyclines: major safety concepts?

    Відповідь

    Gastrointestinal or esophageal irritation, photosensitivity, and effects on developing teeth and bone are key patterns.

  98. Картка 98

    Питання

    Which class is often suggested by the ending -dronate?

    Відповідь

    Bisphosphonates, such as alendronate and risedronate. Confirm the individual agent and formulation.

  99. Картка 99

    Питання

    Dihydropyridine calcium-channel blockers: common uses?

    Відповідь

    Hypertension and angina, using vascular smooth-muscle relaxation to reduce arterial tone.

  100. Картка 100

    Питання

    Inhaled antimuscarinics: common use?

    Відповідь

    Maintenance bronchodilation, especially in COPD; selected agents also serve as add-on asthma therapy.

  101. Картка 101

    Питання

    Which class is often suggested by the ending -gliflozin?

    Відповідь

    SGLT2 inhibitors, such as empagliflozin and dapagliflozin.

  102. Картка 102

    Питання

    Bisphosphonates: major safety concepts?

    Відповідь

    Upper-GI irritation with oral agents, hypocalcemia, and rare osteonecrosis of the jaw or atypical femur fracture.

  103. Картка 103

    Питання

    TNF inhibitors: core mechanism?

    Відповідь

    They neutralize tumor necrosis factor signaling, reducing downstream inflammation.

  104. Картка 104

    Питання

    DPP-4 inhibitors: core mechanism?

    Відповідь

    They inhibit DPP-4, prolonging endogenous incretin activity and increasing glucose-dependent insulin release.

  105. Картка 105

    Питання

    Inhaled corticosteroids: core mechanism?

    Відповідь

    They activate glucocorticoid receptors in airway cells, reducing inflammatory gene expression and airway inflammation.

  106. Картка 106

    Питання

    Statins: core mechanism?

    Відповідь

    They inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis and increasing hepatic LDL-receptor activity.

  107. Картка 107

    Питання

    Adalimumab, infliximab, and etanercept belong to which class?

    Відповідь

    TNF inhibitors. The class has no single specific shared suffix: -mab is broad, and etanercept ends in -cept.

  108. Картка 108

    Питання

    Triptans: core mechanism?

    Відповідь

    They activate serotonin 5-HT1B/1D receptors, reducing trigeminal signaling and causing cranial vasoconstriction.

  109. Картка 109

    Питання

    DPP-4 inhibitors: common use?

    Відповідь

    Type 2 diabetes, using enhanced endogenous incretin signaling to improve glucose-dependent insulin release.

  110. Картка 110

    Питання

    Fluoroquinolones: core mechanism?

    Відповідь

    They inhibit bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication.

  111. Картка 111

    Питання

    Inhaled corticosteroids: major safety concepts?

    Відповідь

    Oral candidiasis and dysphonia are important local effects; systemic effects become more relevant with higher exposure.

  112. Картка 112

    Питання

    Which class is suggested by the ending -statin?

    Відповідь

    HMG-CoA reductase inhibitors, or statins, such as atorvastatin and rosuvastatin.

  113. Картка 113

    Питання

    TNF inhibitors: common uses?

    Відповідь

    Selected autoimmune inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis-related conditions.

  114. Картка 114

    Питання

    Triptans: major safety concepts?

    Відповідь

    Vasoconstrictive risk in coronary, cerebrovascular, or peripheral vascular disease, plus tingling, flushing, or chest pressure called triptan sensations.

  115. Картка 115

    Питання

    Which class is suggested by the ending -gliptin?

    Відповідь

    DPP-4 inhibitors, such as sitagliptin and linagliptin.

  116. Картка 116

    Питання

    Fluoroquinolones: common use?

    Відповідь

    Selected serious or resistant bacterial infections when their spectrum and risk profile fit the infection.

  117. Картка 117

    Питання

    Which patterns often suggest an inhaled corticosteroid?

    Відповідь

    -sonide or -sone often appear, as in budesonide or fluticasone, but these endings are not class-specific.

  118. Картка 118

    Питання

    Statins: major safety concepts?

    Відповідь

    Muscle symptoms and rare rhabdomyolysis or liver injury; pregnancy is a major risk context, although FDA no longer applies a blanket class contraindication.

  119. Картка 119

    Питання

    TNF inhibitors: major safety concepts?

    Відповідь

    Serious infections and reactivation of tuberculosis or hepatitis B are central concerns; other warnings vary by agent.

  120. Картка 120

    Питання

    Triptans: common use?

    Відповідь

    Acute treatment of migraine attacks; they are not general-purpose analgesics or routine migraine preventives.

  121. Картка 121

    Питання

    DPP-4 inhibitors: major safety concepts?

    Відповідь

    Severe joint pain and pancreatitis are warnings; some agents also carry a heart-failure warning.

  122. Картка 122

    Питання

    Which class is suggested by the ending -floxacin?

    Відповідь

    Fluoroquinolone antibiotics, such as ciprofloxacin and levofloxacin.

  123. Картка 123

    Питання

    Inhaled corticosteroids: common use?

    Відповідь

    Controller therapy for asthma and selected COPD regimens; they reduce inflammation rather than acting as standalone rescue bronchodilators.

  124. Картка 124

    Питання

    Statins: common uses?

    Відповідь

    Lowering LDL cholesterol and reducing atherosclerotic cardiovascular risk.

  125. Картка 125

    Питання

    Which class is suggested by the ending -triptan?

    Відповідь

    Triptan antimigraine agents, such as sumatriptan and rizatriptan.

  126. Картка 126

    Питання

    Fluoroquinolones: major safety concepts?

    Відповідь

    Potentially disabling tendon, muscle, joint, nerve, and CNS effects, plus a rare risk of aortic aneurysm or rupture in susceptible people.

Abstract pharmacology study cover showing an unmarked capsule and tablet encircled by six colorful receptor, channel, enzyme, and signaling motifs on a navy field.

126 карток

Pharmacology Drug Class Flashcards: Mechanisms, Uses & Safety Patterns

Вивчати цю колоду безкоштовно

Відкриється Nibomo, і ви зможете почати навчання.